VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity
Key Points: VICTORIA and VICTOR and were randomized trials that evaluated vericiguat versus placebo in HFrEF patients with and without recent decompensation, respectively.... Read more.
SUMMIT: Tirzepatide Improved Renal Function in Patients with HFpEF, Obesity, and CKD
Key Points The SUMMIT randomized control trial demonstrated that tirzepatide significantly reduced worsening heart failure events among patients with HFpEF and obesity... Read more.
EKSTROM Trial: Low-dose Colchicine Reduced Total Plaque Volume on CCTA, but Not Low Attenuation Plaque
Key Points The COLCOT trial demonstrated colchicine improved coronary plaque characteristics in patients with acute coronary syndrome compared with placebo. EKSTROM... Read more.
GCVRC: Controlling Hypertension and Stopping Smoking at Midlife Associated With Greatest Gains in Additional Life-years Free of CVD
Key Points Five classic risk factors – HTN, DM, HLD, underweight/obesity, and smoking – account for 50% of the global burden of CV disease. The purpose of... Read more.
ALLEPRE: Fully Nursing-Led Heart Health Counseling Program Reduces CV Outcomes After ACS
Key Points Nurses are increasingly responsible for cardiovascular risk management, but randomized data supporting this approach is lacking, especially for secondary... Read more.
HOST-BR: 3 Months Of DAPT Might be Reasonable For Both Low- And High-Bleeding Risk Patients After PCI With DES
Key Points After DES placement, guidelines recommend considering shorter DAPT duration (e.g. 1-3 months) for those with high bleeding risk (HBR) and longer DAPT... Read more.
SOUL: Oral Semaglutide Reduced CV Events In High-Risk Patients With T2DM with ASCVD or CKD
Key Points Injectable semaglutide, a GLP-1 receptor agonist, reduces CV events in patients with T2DM, however whether the oral form of semaglutide confers the same... Read more.
FLOW Trial: Renal Benefits of Semaglutide in T2DM Similar Regardless of Baseline CV Risk
Key Points Both chronic kidney disease (CKD) and cardiovascular disease (CVD) are prevalent in type 2 diabetes (T2DM), contributing to morbidity and mortality. The... Read more.
ARREST-AF: Aggressive Risk Factor Management After AF Ablation Reduces Arrythmia Recurrence at 12 Months
Key Points Observation data has suggested that improving cardiometabolic risk factors after AF ablation may reduce the recurrence of arrythmias. The ARREST-AF trial... Read more.
SUMMIT CMR: Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related HFpEF
Key Points Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with increased left ventricular (LV) concentric remodeling and paracardiac... Read more.